2. Cell Cycle/DNA Damage Cytoskeleton Antibody-drug Conjugate/ADC Related
  3. Microtubule/Tubulin Antibody-Drug Conjugates (ADCs)
  4. Anetumab ravtansine

Anetumab ravtansine  (Synonyms: BAY 94-9343)

目录号: HY-141606
技术支持

Anetumab ravtansine (BAY 94-9343) 是一种靶向类玉米蛋白 (maytansinoid) 微管蛋白 (tubulin) 的抗体药物偶联物 (ADC)，效力强、具有选择性。Anetumab ravtansine 由 maytansoid 微管蛋白抑制剂 DM4 偶联人抗间皮素抗体组成。Anetumab ravtansine 在患者源性异种移植瘤模型中显示抗肿瘤药效，其效力与在间皮素表达量相关。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Anetumab ravtansine Chemical Structure

Anetumab ravtansine Chemical Structure

CAS No. : 1375258-01-7

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 是否有货
50 mg   询价  
100 mg   询价  
250 mg   询价  

* Please select Quantity before adding items.

Customer Review

Anetumab ravtansine 相关抗体

Top Publications Citing Use of Products

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Anetumab ravtansine (BAY 94-9343) is a selective and highly potent antibody-drug conjugate (ADC) to target maytansinoid tubulin. Anetumab ravtansine consists of a human anti-mesothelin antibody conjugated to the maytansinoid tubulin inhibitor DM4. Anetumab ravtansine shows antitumor efficacy correlated with the amount of mesothelin expressed in patient-derived xenograft tumor models[1].

体外研究
(In Vitro)

Anetumab ravtansine (0.01-300 nM; 4 或 24 h) 在间皮素表达细胞中表现出强大的选择性的细胞毒性，IC50 为0.72 nM，但不影响间皮素阴性或非增殖细胞[1]。
Anetumab ravtansine 还诱导相邻间皮阴性肿瘤细胞的旁观者效应[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Anetumab ravtansine 相关抗体:

Cell Viability Assay[1]

Cell Line: MIA PaCa-2 and HT-29; OVCAR-3; and NCI-H226
Concentration: 0.01 nM-300 nM
Incubation Time: 24 hours
Result: Inhibited cell viability with IC50s of 1.59 nM (MIA PaCa-2), 0.715 nM (HT-29), 1.59 nM (OVCAR-3), and 5.72 nM (NCI-H226), respectively.
体内研究
(In Vivo)

Anetumab ravtansine (10 mg/kg; 静脉注射) 特异性定位于间皮阳性肿瘤，显示出抗肿瘤活性；并在皮下和原位异种移植模型中抑制肿瘤生长[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Subcutaneous and orthotopic xenograft models: MIA PaCa, HT29, OVCAR-3, NCI-H226 and so on (NMRI nu/nu mice: 18-25 g, 7-10 weeks old)[1]
Dosage: 2.7 mg/kg (0.05 mg/kg DM4), 10.6 mg/kg (0.2 mg/kg DM4)
Administration: MF-T, or S-methyl-DM4 on days 5, 8, and 12 (mice implanted with MIA PaCa or HT29 meso cells); on days 33, 36, and 40 (OVCAR-3); on days 78, 81, 84, 127, 130, and 133 (NCI-H226); on days 15, 18, and 22 (OVCAR-3- s-05 orthotopic); on days 7, 10, and 13 (HT29 titration); Q3Dx3 starting on day 0 (PAXF736); Q3Dx3 starting on day 29 (OVCAR6719); or Q4Dx3 starting on day 34 (Meso7212) after tumor cell inoculation.
Result: Resulted in complete tumor eradication at 10.6 mg/kg (0.2 mg/kg DM4), lasting for at least 17 weeks following the final treatment.
Eradicated tumors in 5 out of 6 animals in the MIA PaCa-2/meso model rather than in HT-29/ meso model at 2.7 mg/kg (0.05 mg/kg DM4).
CAS 号
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
参考文献

Anetumab ravtansine 相关分类

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Anetumab ravtansine1375258-01-7BAY 94-9343Microtubule/TubulinAntibody-Drug Conjugates (ADCs)Antibody-Drug ConjugatesInhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
Anetumab ravtansine
目录号：
HY-141606
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z